Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593424 | SCV000706114 | pathogenic | not provided | 2017-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000593424 | SCV001776517 | pathogenic | not provided | 2020-12-22 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 26076142, 31343788, 10220506) |
MGZ Medical Genetics Center | RCV002289890 | SCV002580290 | pathogenic | Alagille syndrome due to a JAG1 point mutation | 2021-09-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002289890 | SCV004298035 | pathogenic | Alagille syndrome due to a JAG1 point mutation | 2022-12-20 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 500252). This premature translational stop signal has been observed in individual(s) with Alagille syndrome (PMID: 10220506, 34185059). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Cys633*) in the JAG1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in JAG1 are known to be pathogenic (PMID: 11180599). |